Insulet | PODD - Sales Revenues

Stock Price
188.31
Daily Change
-1.25 -0.66%
Monthly
-9.47%
Yearly
-27.44%
Q2 Forecast
185.50

Insulet reported $783.8M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Abbott USD 11.16B 300M Mar/2026
Align Technology USD 1.05B 54.3M Dec/2025
AtriCure USD 140.5M 6.2M Dec/2025
Avanos Medical USD 180.9M 3.1M Dec/2025
Baxter International USD 2.97B 130M Dec/2025
Becton, Dickinson and Co. USD 5.3B 600M Dec/2025
Boston Scientific USD 5.2B 90M Mar/2026
Cardinal Health USD 65.63B 1.63B Dec/2025
Cooper Companies USD 1.02B 41.1M Dec/2025
Dexcom USD 1.26B 50M Dec/2025
Edwards Lifesciences USD 1.65B 80M Mar/2026
Eli Lilly USD 19.3B 1.7B Dec/2025
Globus Medical USD 826.4M 57.4M Dec/2025
ICU Medical USD 540.7M 3.7M Dec/2025
Inogen USD 74.93M 504K Sep/2024
Insulet USD 783.8M 77.5M Dec/2025
Integra LifeSciences USD 434.9M 32.84M Dec/2025
J&J USD 24.1B 500M Mar/2026
Masimo USD 412.5M 41M Dec/2025
Medtronic USD 9B 39M Jan/2026
Merit Medical Systems USD 393.9M 9.7M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Solventum Corp USD 1.99B 110M Dec/2025
Stryker USD 7.2B 1.14B Dec/2025
Tandem Diabetes Care USD 290.4M 41.15M Dec/2025
Teleflex USD 568.98M 344.02M Dec/2025
West Pharmaceutical Services USD 844.9M 39.9M Mar/2026
Zimmer Biomet Holdings USD 2.24B 240M Dec/2025